ERS Genomics licenses CRISPR gene editing technology to Bioneer to further advance preclinical disease modelling

Posted on by zymecom

DUBLIN, Ireland, and Hørsholm, Denmark, 04 June, 2019: ERS Genomics Limited and Bioneer A/S today announced the signing of a license agreement providing Bioneer access to CRISPR/Cas9 genome editing technology intellectual property. Bioneer, a Denmark based life science research and technology provider, will utilize CRISPR/Cas9 technology to generate a range of innovative human cell based disease models.

Under the terms of the license, Bioneer is able to generate and commercialize CRISPR-edited cell based models, broadening its core capabilities and expanding on Bioneer’s expertise in biomedical research support.

Eric Rhodes, CEO of ERS Genomics, said:Bioneer has proven expertise in a broad array of biomedical fields. Adding CRISPR/Cas9 to their toolbox ensures they remain on the leading edge of technology. We are very pleased that Bioneer chose to expand on its service offering by licensing CRISPR/Cas9 technology through ERS Genomics.”

“This cutting-edge technology will complement Bioneer’s competences in advanced preclinical disease modelling.stated Lars H. Pedersen, CEO of Bioneer. Christian Clausen, CSO of Bioneer continues:Bioneer is working with both industry and academia to solve complex disease relevant questions by using advanced disease modelling. The CRISPR/Cas9 tools will enable clients and collaborators to precisely tailor their preclinical modelling strategies to their specific needs for predictive in vitro models. ”

Financial details of the agreement were not disclosed.

This entry was posted in News from Zyme and the companies we work with. Bookmark the permalink.